A randomized controlled study of specific high-titer adenovirus neutralizing antibody plasma in the treatment of severe adenovirus pneumonia in children

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041319

Enrollment

Unknown

Registered

2020-12-23

Start date

2020-12-22

Completion date

Unknown

Last updated

2021-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe ADV pneumonia in children

Interventions

SHTANAP:SHTANAP

non-SHTANAP:non-SHTANAP

Eligibility

Sex/Gender

All

Age

No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Older than 30 days and younger than 18 years; 2. Children who diagnosed with severe pneumonia; 3. Throat swab or deep sputum PCR is diagnosed as adenovirus infection, and sub-grouping is performed; 4. SOFA score is greater than or equal to 5 or Murray lung injury score is greater than 2.

Exclusion criteria

Exclusion criteria: 1. Children whose parents do not agree to the use of plasma therapy and cannot cooperate with the treatment and observation of curative effects; 2. Children who have been severely allergic to blood transfusion products; 3. The main infection is non-adenovirus; 4. Children who have serious underlying diseases (including chronic lung diseases, complicated Congenital heart disease).

Design outcomes

Primary

Measure	Time frame
mortality;	—

Countries

China

Contacts

Public ContactYiyu Yang

Guangzhou Women and Children's Medical Center

yangyy65@yahoo.com+86 18902268086

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026